| Market Cap | ₹51,221Cr |
| ROE | 14.89% |
| P/E Ratio(TTM) | 67.95 |
| EPS(TTM) | 26.71 |
| P/B Ratio | 5.79 |
| Dividend Yield | 0.14% |
| Industry P/E | 33.42 |
| Book Value | 313.59 |
| Debt to Equity | 0.28 |
| Face Value | 1 |
| Parent Organisation | Glenmark Pharmaceuticals Limited |
| Managing Director | Mr. Glenn Saldanha |
| NSE Symbol | GLENMARK |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | NA (0.00%) | 38.74 | ||
| Cipla | NA (0.00%) | 22.36 | ||
| Dr Reddy's Laboratories | NA (0.00%) | 17.53 | ||
| Zydus Lifesciences | NA (0.00%) | 18.88 |